ADARx Pharmaceuticals, backed by AbbVie, files for IPO with three RNAi drugs in clinical trials

ADARx Pharmaceuticals, an RNA interference biotech based in San Diego, disclosed its plan to go public in a Friday night SEC filing. The company aims to capitalize on the current momentum in biotech IPOs.

The filing indicates that ADARx will list its shares on a major U.S. exchange, though the specific exchange and pricing details were not provided. The move follows the company's development of three RNAi therapeutics that are currently in clinical trials.

ADARx is affiliated with AbbVie, which has supported the company’s research efforts. The announcement highlights the firm’s strategy to leverage its pipeline and partnership to attract public market investors.

No financial terms, valuation, or timeline for the offering were disclosed in the filing.